P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Lei Deng
Meta Tag
Speaker Lei Deng
Topic Metastatic NSCLC: Immunotherapy - Retrospective
immunotherapy drug
metastatic non-small cell lung cancer
progression-free survival
best response
durable progression-free survivors
complete response
partial response
stable disease
Powered By